787 related articles for article (PubMed ID: 25284317)
21. Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson's disease.
Lv QK; Tao KX; Wang XB; Yao XY; Pang MZ; Liu JY; Wang F; Liu CF
Inflamm Res; 2023 Mar; 72(3):443-462. PubMed ID: 36598534
[TBL] [Abstract][Full Text] [Related]
22. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.
Cookson MR
Nat Rev Neurosci; 2010 Dec; 11(12):791-7. PubMed ID: 21088684
[TBL] [Abstract][Full Text] [Related]
23. The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.
Cresto N; Gardier C; Gubinelli F; Gaillard MC; Liot G; West AB; Brouillet E
Eur J Neurosci; 2019 Feb; 49(3):339-363. PubMed ID: 30269383
[TBL] [Abstract][Full Text] [Related]
24. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
[TBL] [Abstract][Full Text] [Related]
25. LRRK2 Ablation Attenuates Αlpha-Synuclein-Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo.
Van der Perren A; Cabezudo D; Gelders G; Peralta Ramos JM; Van den Haute C; Baekelandt V; Lobbestael E
Neurotherapeutics; 2021 Apr; 18(2):949-961. PubMed ID: 33594532
[TBL] [Abstract][Full Text] [Related]
26. Microglia and astrocyte dysfunction in parkinson's disease.
Kam TI; Hinkle JT; Dawson TM; Dawson VL
Neurobiol Dis; 2020 Oct; 144():105028. PubMed ID: 32736085
[TBL] [Abstract][Full Text] [Related]
27. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
28. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
[TBL] [Abstract][Full Text] [Related]
29. LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein.
Marker DF; Puccini JM; Mockus TE; Barbieri J; Lu SM; Gelbard HA
J Neuroinflammation; 2012 Nov; 9():261. PubMed ID: 23190742
[TBL] [Abstract][Full Text] [Related]
30. α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.
Covy JP; Giasson BI
Neurotoxicology; 2011 Oct; 32(5):622-9. PubMed ID: 21238487
[TBL] [Abstract][Full Text] [Related]
31. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway.
Carballo-Carbajal I; Weber-Endress S; Rovelli G; Chan D; Wolozin B; Klein CL; Patenge N; Gasser T; Kahle PJ
Cell Signal; 2010 May; 22(5):821-7. PubMed ID: 20074637
[TBL] [Abstract][Full Text] [Related]
32. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
Qing H; Wong W; McGeer EG; McGeer PL
Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Exposure to PFE-360 in the AAV-α-Synuclein Rat Model: Findings and Implications.
Andersen MA; Sotty F; Jensen PH; Badolo L; Jeggo R; Smith GP; Christensen KV
eNeuro; 2019; 6(6):. PubMed ID: 31685675
[TBL] [Abstract][Full Text] [Related]
34. Leucine-rich repeat kinase 2-related functions in GLIA: an update of the last years.
Filippini A; Gennarelli M; Russo I
Biochem Soc Trans; 2021 Jun; 49(3):1375-1384. PubMed ID: 33960369
[TBL] [Abstract][Full Text] [Related]
35. Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates.
Rostami J; Mothes T; Kolahdouzan M; Eriksson O; Moslem M; Bergström J; Ingelsson M; O'Callaghan P; Healy LM; Falk A; Erlandsson A
J Neuroinflammation; 2021 Jun; 18(1):124. PubMed ID: 34082772
[TBL] [Abstract][Full Text] [Related]
36. Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
Caesar M; Felk S; Zach S; Brønstad G; Aasly JO; Gasser T; Gillardon F
Glia; 2014 Jul; 62(7):1075-92. PubMed ID: 24652679
[TBL] [Abstract][Full Text] [Related]
37. LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.
Esteves AR; Swerdlow RH; Cardoso SM
Exp Neurol; 2014 Nov; 261():206-16. PubMed ID: 24907399
[TBL] [Abstract][Full Text] [Related]
38. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
[TBL] [Abstract][Full Text] [Related]
39. Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders.
Puccini JM; Marker DF; Fitzgerald T; Barbieri J; Kim CS; Miller-Rhodes P; Lu SM; Dewhurst S; Gelbard HA
J Neurosci; 2015 Apr; 35(13):5271-83. PubMed ID: 25834052
[TBL] [Abstract][Full Text] [Related]
40. LRRK2 and Proteostasis in Parkinson's Disease.
Pérez-Carrión MD; Posadas I; Solera J; Ceña V
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
